Clinical Trials

Cancer Type: Sarcoma


2013-0152
A091102: Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
This study is for patients who have a soft tissue sarcoma that has spread or recurred.

The purpose of this study is to see the effects, good and/or bad, of MLN8237 on patients with sarcoma. The goal of this study is to see if there is any effect of this drug in treating sarcoma.

MLN8237 is a new investigational drug currently being tested for treatment of sarcoma. Cancer research has shown that there are many proteins within cancer that cause it to grow continuously. Aurora kinase is one of those proteins. MLN8237 is a pill that blocks the activity of Aurora kinase. All subjects will take MLN8237 pills by mouth twice a day for 7 days and then take no pills for 14 days. This cycle will be repated as long as the sarcoma is not getting worse and side effects are tolerable.

 

Forms: